Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 17/20 | 0.59 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14817785 | 1.00 | IL23R (0.59) | IL23RUTS2R | |
| SCHEMBL30710492 | 1.00 | IL23R (0.59) | IL23RUTS2R | |
| Acetic Acid SCHEMBL29377757 | 0.99 | IL23R (0.59) | IL23RUTS2R | |
| Acetic Acid SCHEMBL29757019 | 0.99 | IL23R (0.59) | IL23RUTS2R | |
| SCHEMBL31721667 | 0.95 | IL23R (0.58) | IL23RUTS2R | |
| SCHEMBL29550452 | 0.94 | IL23R (0.61) | IL23RUTS2R | |
| SCHEMBL29550921 | 0.94 | IL23R (0.64) | IL23R | |
| SCHEMBL29550887 | 0.94 | IL23R (0.64) | IL23R | |
| SCHEMBL29550903 | 0.94 | IL23R (0.62) | IL23RUTS2R | |
| SCHEMBL29391843 | 0.93 | IL23R (0.65) | IL23RUTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998010786-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SYNDROME X OF REAVEN | COHEN YAROM (IL) | 1998-03-19 | — | — | WO | claimed |
| US-20220047679-A1 | COMBINATION THERAPY | ANTISENSE THERAPEUTICS LTD (AU) | 2022-02-17 | — | — | US | disclosed |
| CN-104551002-B | Method for preparing quincuncial platinum nanoparticles by taking lanreotide acetate as template | 燕山大学 | 2017-02-22 | — | — | CN | disclosed |
| CN-104551003-B | A kind of method preparing Platinum Nanoparticles screw rod for template with lanreotide acetate | 燕山大学 | 2016-08-24 | — | — | CN | disclosed |
| CN-104551002-A | Method for preparing quincuncial platinum nanoparticles by taking lanreotide acetate as template | UNIV YANSHAN | 2015-04-29 | — | — | CN | disclosed |
| CN-104551003-A | Method for preparing nano-platinum screw rod by taking lanreotide acetate as template | UNIV YANSHAN | 2015-04-29 | — | — | CN | disclosed |
| EP-1340979-A2 | Neuropeptide receptor and uses thereof | Pfizer Limited (GB) | 2003-09-03 | — | — | EP | disclosed |
| EP-0835662-A2 | A drug for the treatment of cancer | National Institute of Immunology (IN) | 1998-04-15 | — | — | EP | disclosed |
| WO-1998010786-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SYNDROME X OF REAVEN | COHEN YAROM (IL) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047679-A1 | COMBINATION THERAPY | GHSR, GHRHR, IGF1R | IL23R 1067/4885UTS2R 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.